USPTO serial 99259208
KAIGENE
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- STEINPFAD, SARAH E
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with KAIGENE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Rockville, MD, US
Rockville, MD, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Devon E. White
Devon E. White Wyrick Robbins Yates & Ponton LLP4101 Lake Boone Trail, Suite 300Raleigh, NC 27607United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases | ACTIVE | — |
| 005 | Pharmaceutical and therapeutic preparations for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical and therapeutic preparations for modulating protein degradation pathways; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders | ACTIVE | — |
| 042 | Research and development in the pharmaceutical and biotechnology fields; Medical and pharmaceutical research services in relation to protein degradation; Providing medical and scientific research information in the field of biochemical, therapeutic, and pharmaceutical preparations; Research and development of platform technology, namely, a biological platform for manufacturing therapeutics for the treatment of autoimmune diseases in the pharmaceutical and biotechnology fields; Research and development of platform technology, namely, a platform for research and development of pharmaceuticals for the treatment of autoimmune diseases in the pharmaceutical and biotechnology fields; Development of platform technology, namely, biotherapeutic platforms for use in manufacturing pharmaceuticals and therapeutics in the pharmaceutical and biotechnology fields; Medical and scientific research, namely, conducting clinical trials for others; Laboratory research services relating to pharmaceuticals; Scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; Providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Custom development of pharmaceutical and biopharmaceutical products; Providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; Pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; Pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; Pharmaceutical research for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins; Testing, inspection, research, or development of pharmaceutical preparations; Providing an on-line searchable database in the field of protein molecules for scientific research purposes; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop treatments for diseases; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop medicines; Providing on-line non-downloadable software program for identifying, searching, and screening protein molecules; Providing on-line non-downloadable software program for searching within a library of protein molecules; Providing medical and scientific research information; Consulting services in the field of genetic science | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kaigene, Inc.
- Other trademarks owned by Kaigene, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named KAIGENE
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 4, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 4, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 29, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 26, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 19, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 19, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 19, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 13, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Feb 13, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Nov 19, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 18, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 4, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 30, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 30, 2025 | NWAP | NEW APPLICATION ENTERED | — |